Ken Griffin Humanigen, Inc Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$0.13 - $0.2 $39 - $60	-300 Reduced 0.96%	31,000 $4,000
Q1 2023 May 15, 2023	SELL	$0.12 - $0.23 $10,128 - $19,412	-84,400 Reduced 72.95%	31,300 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.2 $261 - $580	-2,900 Reduced 2.45%	115,700 $13,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $34,215 - $688,862	-228,100 Reduced 65.79%	118,600 $21,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.